Imaging biomarkers for Alzheimer’s disease include medial temporal lobe atrophy (MTLA) depicted on CT or MRI, and patterns of reduced metabolism on FDG-PET. To investigate whether MTLA on head CT predicts the diagnostic usefulness of an additional FDG-PET scan. Participants had a clinical diagnosis of Alzheimer’s disease (AD; n=37), dementia with Lewy bodies (DLB; n=30), or were similarly aged controls (n=30). We visually rated MTLA on coronally reconstructed CT scans and, separately and blind to CT ratings, abnormal appearances on FDG-PET scans.
- Alzheimer’s disease
- imaging biomarkers
- temporal lobe atrophy
Firbank, M., Lloyd, JJ., Williams, ED., Barber, R., Colloby, SJ., Barnett, NA., Olsen, K., Davison, C., Donaldson, C., Herholz, K., & O'Brien, JT. (2016). An evidence based algorithm for the utility of FDG-PET for diagnosing AD according to presence of medial temporal lobe atrophy. British Journal of Psychiatry, 208(5), 491-496. https://doi.org/10.1192/bjp.bp.114.160804